Download PDF
Thromb Haemost 1998; 79(05): 932-937
DOI: 10.1055/s-0037-1615097
Review Article
Schattauer GmbH

Prophylactic Use of Factor VIII: an Economic Evaluation

Rhonda L. Bohn
1   From the Program for the Analysis of Clinical Strategies, Brigham and Women’s Hospital, Boston, MA, USA
,
Jerry Avorn
1   From the Program for the Analysis of Clinical Strategies, Brigham and Women’s Hospital, Boston, MA, USA
,
Robert J. Glynn
1   From the Program for the Analysis of Clinical Strategies, Brigham and Women’s Hospital, Boston, MA, USA
,
Igor Choodnovskiy
1   From the Program for the Analysis of Clinical Strategies, Brigham and Women’s Hospital, Boston, MA, USA
,
Rudy Haschemeyer
1   The Mount Sinai Medical Center, New York, NY, USA
,
Louis M. Aledort
1   The Mount Sinai Medical Center, New York, NY, USA
› Author AffiliationsThis research was supported in part by a grant from Centeon.
Further Information

Publication History

Received 05 November 1997

Accepted after revision 17 December 1997

Publication Date:
07 December 2017 (online)

    Permissions and Reprints

Summary

Background: Since the introduction of exogenous factor VIII therapy, several studies have explored the clinical benefits of prophylactic use of factor VIII. Little research, though, has focused on the economic aspects of this regimen. We conducted a cost analysis using data from the Orthopedic Outcomes Study, a prospective, cross-national study of the clinical outcomes associated with different patterns of factor VIII utilization to examine the health care costs incurred and expenditures averted in patients receiving on-demand versus prophylactic use of factor VIII in hemophilia. Methods and Analysis: 831 patients with severe hemophilia aged 1 to 31 years, from 19 centers around the world were included in the cost analysis. Patients were categorized into three groups according to the number of weeks during the study years in which they received prophylactic regimens of factor VIII. For each subject, we estimated the costs of hospitalization, surgery, days lost from school or work, and factor VIII utilization. Costs were then stratified by age and by joint score to assess confounding, and a multivariate model developed to determine the relationship between use of factor VIII prophylaxis and total costs, while controlling for potential confounders.

Results: Patients who received factor VIII episodically incurred substantially greater disability-related costs (days lost from school or work, days hospitalized due to hemophilia, surgery) than patients who received factor VIII prophylactically for some or all of the study period. For all treatment regimens, most disability-related costs were accounted for by hospitalization for hemophilia-related conditions. The cost of factor VIII itself was substantial in all treatment categories but was highest among patients who received year-round prophylaxis, exceeding the savings resulting from reduced disability and other health care expenditures.

Conclusions: Reductions in non-factor health care costs and disability associated with prophylactic use of factor VIII in hemophilia were substantial and helped somewhat to offset the much higher costs of this regimen. For certain subgroups, frequent episodic treatment may be more expensive than full-time prophylaxis. However, because of the very high cost of year-round prophylactic use of factor VIII, total health care expenditures were highest among patients receiving this therapeutic regimen. However, because prophylaxis clearly offers important clinical benefits, this approach may be warranted on medical rather than economic grounds.

 

  • References

  • 1 Rosendaal FR, Varekamp I, Smith C, Brocker-Vriends AHJT, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briet E. Mortality and causes of death in Dutch hemophiliacs, 1973-1986. Br J Haematology 1989; 71: 71-6.
    CrossrefPubMedGoogle Scholar
  • 2 Ross-Degnan D, Soumerai SB, Avorn J, Bohn RL, Bright R, Aledort LM. Hemophilia home treatment. Economic analysis and implications for health policy. 1995; Int J Technol Assess Health Care 11 (02) 327-44.
    CrossrefPubMedGoogle Scholar
  • 3 Bona RD, Weinstein RA, Weisman SJ, Bartolomeo A, Rickles FR. The use of continuous infusion of factor concentrates in the treatment of hemophilia. Am J Hematol 1989; 32: 8-13.
    CrossrefPubMedGoogle Scholar
  • 4 Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematology 1992; 82: 729-34.
    CrossrefPubMedGoogle Scholar
  • 5 Ahlberg A. Hemophilia in Sweden. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Ortho Scan 1965; 77 Suppl 5-99.
    PubMedGoogle Scholar
  • 6 Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Int Med 1992; 232: 2225-32.
    PubMedGoogle Scholar
  • 7 Lusher JM. Prophylaxis in children with hemophilia: Is it optimal treatment?. Thromb Haemost 1997; 78: 726-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Shanbrom E, Thelin GM. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. JAMA 1969; 208 (10) 1853-6.
    CrossrefPubMedGoogle Scholar
  • 9 Aledort LM. Prophylaxis: the next haemophilia treatment. J Int Med 1992; 232: 1-2.
    CrossrefPubMedGoogle Scholar
  • 10 van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haemat 1971; 45: 120-7.
    CrossrefPubMedGoogle Scholar
  • 11 Petterson H, Nilsson IM, Hedner U, Norehn K, Ahlberg A. Radiologic evaluation of prophylaxis in severe haemophilia. Acta Paediatr Scand 1981; 70: 565-70.
    CrossrefPubMedGoogle Scholar
  • 12 Aronstam A, Arblaster PG, Rainsford SG, Turk P, Slattery M, Alderson MR, Hall DE, Kirk PJ. Prophylaxis in haemophilia: A double-blind controlled trial. Br J Hemat 1976; 33: 81-90.
    CrossrefPubMedGoogle Scholar
  • 13 Editorial.. Prophylaxis in haemophilia. Lancet 1971; 705 (01) 917.
    PubMedGoogle Scholar
  • 14 Editorial.. Hemophilia prophylaxis. JAMA 1970; 212 (13) 2256-7.
    CrossrefPubMedGoogle Scholar
  • 15 Smith PS, Teutsch SM, Shaffer PA, Rolka H, Evatt B. Episodic versus prophylactic infusions for hemophilia A: A cost-effectiveness analysis. J Pediatr 1996; 129: 424-31.
    CrossrefPubMedGoogle Scholar
  • 16 Kasper CK, Dietrich SL, Rapaport SI. Hemophilia prophylaxis with factor VIII concentrate. Arch Intern Med 1970; 125: 1004-9.
    CrossrefPubMedGoogle Scholar
  • 17 Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Ped Hematology/Oncology 1991; 13 (03) 280-7.
    PubMedGoogle Scholar
  • 18 Nilsson IM, Hedner U, Ahlberg A. Hemophilia prophylaxis in Sweden. Acta Paediatr Scand 1976; 65: 129-35.
    CrossrefPubMedGoogle Scholar
  • 19 Ramsay DM, Parker AC. A trial of prophylactic replacement therapy in haemophilia and Christmas disease. J Clin Path 1973; 26: 243-7.
    CrossrefPubMedGoogle Scholar
  • 20 Linney DR, Lazerson J. Hemophilia: Cost considerations for prescribing therapeutic materials. Transfusion 1979; 19: 57-9.
    CrossrefPubMedGoogle Scholar
  • 21 Smith PS, Keyes NC, Forman EN. Socioeconomic evaluation of a state-funded comprehensive hemophilia-care program. N Engl J Med 1982; 306: 575-9.
    CrossrefPubMedGoogle Scholar
  • 22 Robinson PM, Tittley P, Smiley RK. Prophylactic therapy in classical hemophilia: a preliminary report. Canad Med Ass J 1976; 97 (11) 559-6.
    PubMedGoogle Scholar
  • 23 Aledort LM, Haschemeyer RH, Pettersson H. A longitudinal study of orthopedic outcomes for severe factor VIII deficient hemophiliacs. J Int Med (October) 1994; 236 (04) 391-9.
    CrossrefPubMedGoogle Scholar
  • 24 Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. 1992; J Int Med 232 (01) 25-32.
    CrossrefPubMedGoogle Scholar
  • 25 Pettersson H, Gilbert M. Musculoskeletal and other haemorrhagic complications. In Diagnostic Imaging in Hemophilia. Berlin: Springer-Verlag; 1985: 55-60.
    Google Scholar
  • 26 Employment and Earnings. U.S. Department of Labor, Bureau of Labor Statistics. 1991-1992.
    PubMedGoogle Scholar
  • 27 Computer-Assisted Hospitalization Analysis for the Study of Efficacy (CHASE). Brigham and Women’s Hospital; Boston, MA: 1992
    Google Scholar
  • 28 Medical Economics Data. Red Book. 1992. Medical Economics Inc.; Mont-vale, NJ.:
    Google Scholar
  • 29 McCullagh P. Regression models for ordinal data (with discussion). 1980; J Roy Statist Soc B 42: 109-42.
    PubMedGoogle Scholar
  • 30 SAS Institute Inc. The LOGISTIC Procedure, in SAS/STAT User’s Guide. Release 6.03 ed Cary, NC: SAS Institute; 1988
    Google Scholar
  • 31 Lipsitz DR, Harrington DP. Analyzing correlated binary data using SAS. Comput Biomed Res 1990; 23: 268-82.
    CrossrefPubMedGoogle Scholar
  • 32 Martinowitz U, Schulman S, Gitel S, Horozowski H, Heim M, Varon D. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A. Br J Haematol 1992; 82 (04) 729-34.
    CrossrefPubMedGoogle Scholar
  • 33 Schulman S, Varon D, Keller N, Gitel S, Martinowitz U. Monoclonal purified F VIII for continuous infusion: stability, microbiological safety and clinical experience. Thromb Haemost 1994; 72 (03) 403-7.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Aledort LM, Bohn RL. Prophylaxis and continuous infusion for hemophilia: can we afford it?. Blood Coagul Fibrinolysis 1996; 7 (Suppl. 01) S35-S7.
    PubMedGoogle Scholar
  • 35 Bjorkman S, Carlsson M, Berntorp E, Stenberg P. Pharmacokinetics of factor VIII in humans. Clin Pharmacokinetics 1992; 22: 385-95.
    CrossrefPubMedGoogle Scholar